Search
Search articles by subject, keyword or author
Advanced search

Smart bullets: hijacking tumor macrophages to unmask cytokine potency

Lai Guan Ng , Florent Ginhoux

Vita ››

PDF (3107KB)
Vita > Cutting Edge > DOI: 10.15302/vita.2026.02.0016
Vita Open AccessPublished:

Smart bullets: hijacking tumor macrophages to unmask cytokine potency

Author information +
History +
Vita () Cite this article
PDF (3107KB)

Solid tumors evade immunotherapy by forming a suppressive myeloid barrier that limits T and NK cell activity. A study recently published at Cell reports myeloid-targeted immunocytokines and NK/T cell enhancers (MiTEs) conditionally activate cytokines within tumors, coupling myeloid reprogramming to effector stimulation; in vivo, MiTEs remodel tumor myeloid states, amplify cytotoxic lymphocyte programs, and improve tumor control, offering a modular strategy for combination immunotherapy.

登录浏览全文

4963

注册一个新账户 忘记密码

Immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 have revolutionized cancer immunotherapy, yet a significant proportion of patients fail to respond. One of the central obstacles is the immunosuppressive tumor microenvironment (TME), often dominated by tumor-associated macrophages (TAMs), which not only physically exclude T cells but also suppress their function through engagement of immunosuppressive receptors such as TREM21. TREM2-expressing TAMs adopt a lipid-associated, metabolically adapted phenotype that promotes immune evasion by dampening antigen presentation, limiting pro-inflammatory cytokine production, and reinforcing checkpoint signaling pathways within the TME2,3. Despite longstanding interest in targeting TAMs, therapeutic strategies aimed at depleting or reprogramming myeloid cells have demonstrated limited efficacy as monotherapies. On the other hand, cytokine-based therapies, particularly those involving Interleukin-2 (IL-2), exhibit potent immunostimulatory capacity but are hampered by systemic toxicities4,5.
In a recent study published at Cell6 von Locquenghien et al., report a protein engineering innovation that elegantly addresses two major challenges in immunotherapy: targeted reprogramming of the TME and selective activation of cytotoxic activities by lymphocytes. To achieve this goal, the authors have generated a new class of immunocytokines (myeloid-targeted immunocytokines and natural killer (NK)/T cell enhancers (MiTEs)). The design logic of MiTEs is based on a sophisticated dual-gating mechanism that requires two tumor-specific conditions for full activation. By fusing a TREM2-blocking antibody to a protease-activatable IL-2 superkine, the authors engineered a molecule that remains inert in circulation, but unleashes dual activity only in the tumor microenvironment — involving myeloid reprogramming and NK/T cell stimulation. This strategy enables spatially restricted immune stimulation while minimizing systemic toxicity through two levels of tumor-selectivity. First, the antibody backbone targets TREM2, a receptor highly enriched on suppressive TAMs. Second, the IL-2 is masked by a substrate specific for MMP14, a protease the authors identified as highly upregulated on TAMs. This ensures that the cytokine "bullet" is only exposed within the protease-rich TME. Importantly, the authors demonstrate that while a non-masked version of the molecule induced lethal systemic toxicity in mice, the protease-activatable MiTE-144 was well-tolerated, leading to no peripheral cytokine storms even at high doses.
Mechanistically, MiTE-144 reprograms TAMs toward a pro-inflammatory phenotype, while simultaneously promoting CD8+ T cell proliferation and stemness, enhancing NK cell activation and cytotoxicity, and attenuating exhaustion and other immunosuppressive programs. Perhaps the most exciting finding is the synergy observed when MiTEs are combined with conventional checkpoint blockade. In aggressive, ICI-resistant murine models (MC38 and MCA205), MiTE-144 monotherapy significantly outperformed anti-PD-1 and anti-CTLA-4 alone. However, the combination of MiTE-144 with anti-CTLA-4 resulted in complete tumor eradication in the majority of mice. Importantly, translational studies using patient-derived tumor fragments further validated the immunomodulatory effects in human tissues.
Despite its promise, this approach faces several challenges. Although MMP14 is enriched in tumors, its expression in healthy tissues may present safety risks in humans. Additionally, the immunogenicity of the engineered fusion protein raises the possibility of anti-drug antibody formation, necessitating careful monitoring in clinical trials. The authors also note that while regulatory T cell (Treg) expansion was managed through combination with anti-CTLA-4 therapy, future iterations of MiTEs may incorporate IL-2 variants with greater effector-cell selectivity or alternative cytokines, such as IL-15 or IL-12, to further enhance therapeutic efficacy and safety.
Overall, this study represents a significant conceptual advance in the design of immunocytokines. Prior efforts to harness cytokines have primarily focused on cis-targeting strategies, such as fusing IL-2 to T cell-directed antibodies (e.g., anti-PD-1–IL-2), which depend on the presence of pre-existing intratumoral T cells. However, such strategies are often ineffective in “cold,” myeloid-dominated tumors where T cells are scarce or dysfunctional. In contrast, MiTEs redefine the therapeutic paradigm by targeting TAMs as a cellular scaffold for IL-2 delivery, thereby enabling trans-activation of neighboring lymphocytes. This strategy co-opts the immunosuppressive architecture of the tumor microenvironment to initiate localized cytotoxic responses.
In summary, von Locquenghien et al. have engineered a “smart bullet” for cancer immunotherapy and provided a blueprint for moving beyond T cell-centric paradigms. This study highlights the promise of integrated strategies that co-target myeloid and lymphoid compartments as a foundation for the next generation of rational, combinatorial cancer therapies.

[1]

Sharma, P., Hu-Lieskovan, S., Wargo, J.A. & Ribas, A. Cell 168, 707–723 (2017).

[2]

Deczkowska, A., Weiner, A. & Amit, I. Cell 181, 1207–1217 (2020).

[3]

Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Nat. Rev. Clin. Oncol. 14, 399–416 (2017).

[4]

Waldmann, T.A. Nat. Rev. Immunol. 6, 595–601 (2006).

[5]

Raeber, M.E., Sahin, D. & Boyman, O. Sci. Transl. Med. 14, eabo5409 (2022).

[6]

von Locquenghien, M. et al. Cell 188, 7099–7117.e26 (2025).

RIGHTS & PERMISSIONS

The Author(s) 2026. Published by Higher Education Press. This is an Open Access article distributed under the terms of the CC BY license (https://creativecommons.org/licenses/by/4.0/).

Cite this article

Download citation ▾
Ng, L., Ginhoux, F. Smart bullets: hijacking tumor macrophages to unmask cytokine potency Vita https://doi.org/10.15302/vita.2026.02.0016 ()
AI Summary AI Mindmap
PDF (3107KB)
Sections
Figures
References

2827

Accesses

0

Citation

Detail

Recommended

AI思维导图

/

〈 〉